SK282549B6 - Spôsob stabilizácie naloxonhydrochloridu - Google Patents

Spôsob stabilizácie naloxonhydrochloridu Download PDF

Info

Publication number
SK282549B6
SK282549B6 SK1092-99A SK109299A SK282549B6 SK 282549 B6 SK282549 B6 SK 282549B6 SK 109299 A SK109299 A SK 109299A SK 282549 B6 SK282549 B6 SK 282549B6
Authority
SK
Slovakia
Prior art keywords
acid
derivatives
stabilizer
naloxone
salts
Prior art date
Application number
SK1092-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK109299A3 (en
Inventor
Bernd Raffelsberger
Original Assignee
G�decke Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G�decke Aktiengesellschaft filed Critical G�decke Aktiengesellschaft
Publication of SK109299A3 publication Critical patent/SK109299A3/sk
Publication of SK282549B6 publication Critical patent/SK282549B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Cereal-Derived Products (AREA)
  • Organic Insulating Materials (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1092-99A 1997-02-14 1998-02-03 Spôsob stabilizácie naloxonhydrochloridu SK282549B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19705537 1997-02-14
PCT/EP1998/000556 WO1998035679A1 (de) 1997-02-14 1998-02-03 Stabilisierung von naloxonhydrochlorid

Publications (2)

Publication Number Publication Date
SK109299A3 SK109299A3 (en) 2000-08-14
SK282549B6 true SK282549B6 (sk) 2002-10-08

Family

ID=7820153

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1092-99A SK282549B6 (sk) 1997-02-14 1998-02-03 Spôsob stabilizácie naloxonhydrochloridu

Country Status (10)

Country Link
EP (1) EP0880352B1 (el)
AT (1) ATE186643T1 (el)
CZ (1) CZ297951B6 (el)
DE (1) DE59800046D1 (el)
ES (1) ES2141631T3 (el)
GR (1) GR3032458T3 (el)
HU (1) HU224964B1 (el)
PL (1) PL190293B1 (el)
SK (1) SK282549B6 (el)
WO (1) WO1998035679A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913152B1 (de) * 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
TR200001828T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003077867A2 (en) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
EP1639997A1 (en) 2002-04-05 2006-03-29 Euro-Celtique S.A. Matrix for sustained, invariant and independant release of active compounds
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
AU2008244936B2 (en) 2007-04-26 2013-02-21 Toray Industries, Inc. Stable solid preparation comprising 4,5-epoxymorphinan derivative
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR101682963B1 (ko) 2008-10-24 2016-12-06 도레이 카부시키가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
US8524276B2 (en) 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2014350135B2 (en) 2013-11-13 2017-08-31 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
EP3177146A4 (en) * 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS276692B6 (cs) * 1990-08-29 1992-07-15 Z Presneho Strojirenstvi Zařízení k řazení hřebíků v násypce plníce
JPH07267862A (ja) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd 経皮吸収貼付剤
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
ATE211906T1 (de) * 1996-03-12 2002-02-15 Alza Corp Zusammensetzung und dosisform mit einem opioid- antagonisten

Also Published As

Publication number Publication date
GR3032458T3 (en) 2000-05-31
HUP0001094A3 (en) 2001-02-28
WO1998035679A1 (de) 1998-08-20
HUP0001094A2 (hu) 2000-09-28
EP0880352A2 (de) 1998-12-02
ES2141631T3 (es) 2000-03-16
CZ289699A3 (cs) 2000-02-16
SK109299A3 (en) 2000-08-14
ATE186643T1 (de) 1999-12-15
CZ297951B6 (cs) 2007-05-02
PL190293B1 (pl) 2005-11-30
DE59800046D1 (de) 1999-12-23
HU224964B1 (en) 2006-04-28
PL335249A1 (en) 2000-04-10
EP0880352B1 (de) 1999-11-17

Similar Documents

Publication Publication Date Title
SK282549B6 (sk) Spôsob stabilizácie naloxonhydrochloridu
EP2416758B1 (en) Antimycotic pharmaceutical composition
AU604061B2 (en) Drug compositions stabilized against oxidation
AU2002243069B2 (en) Novel amlodipine camsylate and method for preparing thereof
US5350582A (en) Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof
AU613196B2 (en) Stable compositions containing esmolol hydrochloride for cardiac conditions
DE29719704U1 (de) Stabile Zubereitungen von Naloxonhydrochlorid
SK9682000A3 (en) Novel polyethoxylated castor oil, process of making the same and formulations thereof
PT2405910E (pt) Derivados de rosuvastatina e atorvastatina
DE4124409B4 (de) Pharmazeutische Zubereitungen
US6004949A (en) Aqueous composition containing cromoglycic acid
RU97108965A (ru) Содержащий ингибитор тромбина стабильный при хранении водный раствор для вливания
RU2296568C1 (ru) Инъекционная лекарственная форма для лечения и профилактики кровепаразитарных и инвазионных заболеваний
SK278421B6 (en) Parenterally applicable pharmaceutical composition containing bis-indole alkaloid and preparation method thereof
US4582845A (en) Pharmaceutical composition for injection
DE69920039T2 (de) Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung
WO2006126825A1 (en) Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
US20070077261A1 (en) Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers
DE2806866A1 (de) Pharmazeutische produkte und ihre anwendung zur verhinderung schaedlicher nebenwirkungen von alkylantiencytostatika
US4616022A (en) Procaterol stabilization
JP2007106736A (ja) 注射用の医薬組成物
JPS58502000A (ja) 置換ピロ−ル
NISHIHATA et al. Enhancement of Small Intestinal Absorption of N, N'-Dimethylcarbamoylmethyl 4-(4-Guanidinobenzoyloxy) Phenylacetate Methanesulfonate (FOY305 [○! R]) in Rats
SAKAIC carbamoylmethyl 4-(4-Guanidinobenzoyloxy) Phenylacetate Methanesulfonate (FOY305®) in Rats
WO1994007493A1 (en) Stabilized compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o-methyl-oxime

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180203